Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423501 · ClinicalTrials.gov registry record · Phase 2
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 306
- Enrollment target
NCT00423501: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00423501 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 306 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (130% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00423501, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 306 participants
- Enrollment target
Study Summary
This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or 20mg every 2 weeks. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.
Interventions
- DRUG Placebo
- DRUG taspoglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
What the finished NCT00423501 record still lists
NCT00423501 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (130% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00423501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00423501 about?
NCT00423501 is a clinical study titled "A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.". This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcu...
What is the current status of trial NCT00423501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 306 participants. The study started on 2007-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00423501?
The interventions under investigation include: Placebo (DRUG), taspoglutide (DRUG).
Who is sponsoring clinical trial NCT00423501?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00423501's enrollment target sits among peer trials
306 165th of 2000 higher than 1,835 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia